Showing 6171-6180 of 7756 results for "".
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers-1/2461215/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston, Texas. He
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies
- 2022 Monkeypox Outbreak: Here’s What Dermatologists Need to Knowhttps://practicaldermatology.com/news/2022-monkeypox-outbreak-heres-what-dermatologists-need-to-know/2461210/As case counts of monkeypox cases increase in Europe and other parts of the globe including the US, dermatologists may have an important role to play in terms of making differential diagnoses. George Han, MD a dermatologist at Lenox Hill Hospital in New York City, spoke to Practical
- June Risser Named General Manager of Premium Skincare Business Unit at Crown Laboratorieshttps://practicaldermatology.com/news/june-risser-named-general-manager-of-premium-skincare-business-unit-at-crown-laboratories/2461207/June Risser is Crown Laboratories, Inc.’s new General Manager of Premium Skincare. She will lead the global business unit which includes StriVectin and Vita Liberata, and she will hold a position on the Executive Leadership Team. Prior to Crown, she was General Man
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- Aspiring Physician with Psoriasis Among AbbVie Scholarship Recipientshttps://practicaldermatology.com/news/aspiring-dermatologist-with-psoriasis-among-abbvie-scholarship-recipients/2461201/AbbVie has awarded 45 scholarships as part of its 2022-2023 AbbVie Immunology Scholarship program. The program, which provides financial support to students living with chronic, immune-mediated diseases pursuing higher education in the United States, received more than 1,000 applic
- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician
- Cynosure Scores $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://practicaldermatology.com/news/cynosure-scores-60-million-follow-on-investment-from-clayton-dubilier-rice/2461199/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that